|

A Multi-Center Observational Trial of Symptomatic, High-Risk Bone Metastases Treated With Percutaneous Ablation and Palliative Radiation Therapy

RECRUITINGSponsored by Society of Interventional Oncology
Actively Recruiting
SponsorSociety of Interventional Oncology
Started2025-10-23
Est. completion2027-07-31
Eligibility
Age21 Years+
Healthy vol.Accepted
Locations6 sites

Summary

The objective of this study is to evaluate real-world outcomes (e.g., pain, patient reported outcomes, skeletal related events, healthcare utilization, etc.) in patients treated with both percutaneous ablation and palliative radiation therapy (RT).

Eligibility

Age: 21 Years+Healthy volunteers accepted
Inclusion Criteria:

* 1\. Skeletal metastasis with localized pain not controlled medically \[recall within last 24 hours of worst pain ≥ 5 using the BPI\]
* 2\. Pain must be from one painful metastatic lesion involving the bone (additional less painful metastatic sites may be present). Extra-osseous extension of disease is allowed (must have some contact with the bone and be causing bone/tumor interface pain)
* 3\. Lesions that are at high-risk of skeletal related events defined as follows:
* a. Minimum Spinal Instability Neoplastic Score (SINS) score ≥ 7 for lesions involving the spine
* b. Pelvic and appendicular lytic lesions with or without cortical breakthrough causing functional/mechanical pain
* 4\. Target lesion amenable to percutaneous ablation with image guidance AND RT by specialists' review
* 5\. No prior targeted radiation therapy or ablation to the index lesion
* 6\. ECOG performance status 0-2
* 7\. Age ≥ 21 years
* 8\. Have signed the current approved informed consent form
* 9\. Willing and able to answer follow-up Patient Reported Outcomes (PRO) surveys (e.g., PROMIS®, BPI, COST-FACIT, and OMED) for up to 12 months
* 10\. Life expectancy \> 3 months

Exclusion Criteria:

* 1\. Any medical or personal condition that, in the opinion of the site investigator, may potentially compromise the safety or compliance of the patient, or may preclude the patient's successful completion of the clinical trial.
* 2\. Target tumor involves a weight-bearing long bone of the lower extremity with the tumor causing \> 50% loss of cortical bone \[MIREL Score ≥ 7\]
* 3\. Skeletal lesions with unstable pathologic fractures requiring immediate surgical stabilization
* 4\. Concurrent participation in other studies that could affect the primary endpoint
* 5\. Target tumor causing clinical or imaging evidence of spinal cord compression

Conditions2

Bone Cancer MetastaticCancer

Locations6 sites

University of California San Diego Moores Cancer Center
San Diego, California, 92093
Kathy Velasco858-822-5677kcvelasco@health.ucsd.edu
Emory University Hospital
Atlanta, Georgia, 30322
Maria Rivas404-712-7962mrivas2@emory.edu
Northside Hospital
Atlanta, Georgia, 30342
Shannon Gleason404-303-3355clinical.trials@northside.com
Mayo Clinic
Rochester, Minnesota, 55905
Desirae Howe-Clayton507-255-0111Howe.desirae@mayo.edu
Washington University
St Louis, Missouri, 63110
Addie Lovato314-362-4263lovato@wustl.edu

Browse More Trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.